Financial Performance - The company's revenue for Q1 2025 was ¥169,136,638.98, a decrease of 14.71% compared to ¥198,307,676.45 in the same period last year[5] - Net profit attributable to shareholders was ¥52,924,282.00, a significant increase of 114.57% from a loss of ¥363,290,638.81 in the previous year[5] - Basic and diluted earnings per share were both ¥0.04, representing a 115.38% increase from -¥0.26 in the same period last year[5] - Operating profit turned positive at ¥93.18 million compared to a loss of ¥433.31 million in the previous period[28] - Net profit for the period was ¥51.26 million, a significant recovery from a net loss of ¥361.14 million in the prior year[28] - The company reported a total comprehensive income of ¥51.22 million, recovering from a loss of ¥360.92 million in the previous year[29] Cash Flow - The net cash flow from operating activities improved by 59.14%, reaching -¥36,693,867.25 compared to -¥89,798,669.28 in the previous year[5] - The net cash flow from operating activities was CNY -36,693,867.25, a 59.14% improvement compared to CNY -89,798,669.28 in the previous year, mainly due to reduced salary and bonus payments[13] - Cash flow from operating activities showed a net outflow of ¥36.69 million, an improvement from a net outflow of ¥89.80 million in the previous period[31] - The net cash flow from investing activities was CNY 43,714,694.14, a 142.95% increase from CNY -101,776,732.65 in the previous year, attributed to the maturity of large deposits and recovery of investment cash[13] - Cash inflow from investment activities was ¥580.96 million, compared to ¥137.93 million in the prior year, indicating a strong recovery[31] - Cash outflow for investment activities increased to ¥537.25 million from ¥239.71 million, reflecting increased investment efforts[31] - The net cash flow from financing activities decreased to CNY -27,698,161.40, a 260.01% decline compared to CNY -7,693,688.13 in the previous year, primarily due to increased cash payments for debt repayment[13] - Net cash flow from financing activities was -$27.70 million, compared to -$7.69 million in the previous period, indicating a significant decline[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,487,572,269.44, a decrease of 0.93% from ¥9,576,915,691.47 at the end of the previous year[5] - Total current assets decreased to CNY 3,296,019,612.54 from CNY 3,781,514,679.73, a decline of about 12.8%[22] - Total liabilities decreased to CNY 1,293,326,789.33 from CNY 1,433,894,606.08, representing a reduction of approximately 9.8%[24] - Total equity attributable to shareholders increased to CNY 7,932,851,074.19 from CNY 7,879,949,193.44, showing a growth of about 0.67%[24] - Non-current assets totaled CNY 6,191,552,656.90, up from CNY 5,795,401,011.74, indicating an increase of about 6.8%[22] Shareholder Information - The company had a total of 146,867 common shareholders at the end of the reporting period[15] - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 16.63% of the shares, totaling 233,391,995 shares[16] - The second-largest shareholder, Guangzhou Biomedical and Health Industry Investment Co., Ltd., owns 10.00% of the shares, totaling 140,344,607 shares[16] Operational Costs - Operating costs increased by 33.18% to ¥116,639,813.97, primarily due to increased amortization of long-term assets related to production[12] - Total operating costs increased to ¥238.18 million from ¥207.95 million, representing a growth of approximately 14.8% year-over-year[27] - Sales expenses rose significantly by 78.43% to ¥45,354,577.50, mainly due to reclassification of expense categories[12] Other Income and Fair Value - The company reported a significant increase in other income, reaching CNY 793,129.91, a 526.82% rise compared to CNY 126,532.41 in the previous period, mainly due to increased penalty income[13] - The company recorded a significant fair value gain of ¥200.73 million, contrasting with a loss of ¥365.57 million in the previous period, highlighting improved market conditions[27] Future Plans and Developments - The company has announced plans to obtain a medical device registration certificate, indicating ongoing efforts in product development[18] - The company plans to hold an online explanation meeting for the 2024 annual report, indicating a commitment to transparency and communication with stakeholders[20] - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[34] Miscellaneous - The first quarter report was not audited, which may affect the reliability of the financial data presented[33] - Current cash and cash equivalents amount to CNY 851,296,028.53, down from CNY 872,086,093.74 at the beginning of the period[21] - Accounts receivable decreased to CNY 1,171,534,622.86 from CNY 1,254,344,767.52, reflecting a reduction of approximately 6.6%[21] - Inventory increased to CNY 202,660,100.27 from CNY 198,214,544.62, reflecting a rise of approximately 2.3%[22] - Short-term borrowings decreased to CNY 117,637,389.36 from CNY 143,534,033.02, a decline of approximately 18%[23] - Cash and cash equivalents net increase was -$20.78 million, compared to a much larger decrease of -$199.21 million in the previous period[32] - The company reported a decrease in cash flow due to foreign exchange fluctuations, amounting to -$100,827.82[32]

广州达安基因股份有限公司（以下简称"公司"）监事会于近日收到监事会 主席朱琬瑜女士递交的书面辞职报告，朱琬瑜女士因工作原因申请辞去公司第八 届监事会主席及监事职务。朱琬瑜女士确认其与公司和公司监事会之间没有不同 意见，也没有任何有关其辞任监事会主席、监事须提呈公司股东注意的事宜。 根据《公司法》和《公司章程》的相关规定，朱琬瑜女士的辞职不会导致公 司监事会成员低于法定最低人数，上述辞职报告自送达监事会时生效。朱琬瑜女 士的离任不会对公司日常生产经营和管理产生影响。截止目前，朱琬瑜女士未持 有本公司股票。 朱琬瑜女士自担任本公司监事期间，忠实、勤勉地履行了各项职责，为公司 的经营发展作出了巨大贡献，公司经营管理层对朱琬瑜女士在职期间为公司所做 的贡献表示诚挚的感谢！ 特此公告。 广州达安基因股份有限公司 证券代码：002030 证券简称：达安基因 公告编号：2025-018 广州达安基因股份有限公司 关于监事会主席辞职的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 28 日 监 事 会 ...

Meeting Overview - The 2024 Annual General Meeting (AGM) of Guangzhou Da'an Gene Co., Ltd. was held on April 18, 2025, combining on-site and online voting methods [4][5] - A total of 593 shareholders and authorized representatives attended the meeting, representing 457,340,573 shares, which is 32.5870% of the total shares [6] Voting Results - The following proposals were approved during the meeting: - The 2024 Board of Directors Work Report received 99.2868% approval [8] - The 2024 Supervisory Board Work Report received 99.2783% approval [9] - The 2024 Financial Settlement Proposal received 99.2832% approval [10] - The 2024 Annual Report and its summary received 99.2876% approval [11] - The 2024 Profit Distribution Proposal received 99.2409% approval, with 74.1529% approval from minority investors [12] - The proposal for expected related party transactions for 2025 received 76.2190% approval [13] - The proposal for cash management using idle funds for 2025 received 99.2478% approval, with 74.3882% approval from minority investors [14] - The proposal regarding the termination of stock listing for a subsidiary received 99.3168% approval [15] Independent Directors' Report - Independent directors provided a detailed report on their activities during 2024, including attendance at board meetings and efforts to protect minority investors' rights [16] Legal Opinion - The meeting was witnessed by lawyers from Beijing Kangda (Guangzhou) Law Firm, who confirmed that the meeting's procedures and resolutions complied with relevant laws and regulations [17][18] Documentation - The resolutions from the AGM and the legal opinion from the law firm are available for review [19]

证券代码：002030 证券简称：达安基因 公告编号：2025-017 广州达安基因股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更前次股东会决议。 3、本次股东会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 4 月 18 日下午 14：30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 4 月 18 日上午 9：15-9：25，9：30-11：30 和下午 13：00-15：00；通 过深圳证券交易所互联网投票系统投票的时间为 2025 年 4 月 18 日上午 9:15 至 2025 年 4 月 18 日下午 15：00 期间的任意时间。 2、会议召开地点：广州市高新技术开发区科学城香山路 19 号公司一楼讲学 厅 5、会议主持人：公司董事长薛哲强先生 6、会议召开的合法、合规性：本次股东会的召开符合《公司法》 ...

北京市康达（广州）律师事务所 关于广州达安基因股份有限公司 2024 年度股东会的法律意见书 康达股会字[2025]第 0008 号 致：广州达安基因股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受广州达安基因股份有 限公司（下称"达安基因"或"公司"）委托，指派律师出席公司 2024 年度股 东会。根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共 和国证券法》（下称"《证券法》"）、《上市公司股东会规则》（下称"《股 东会规则》"）等法律、法规、规范性文件以及《广州达安基因股份有限公司章 程》（下称"达安基因《公司章程》"）的规定，本所律师对本次股东会的召集、 召开程序、召集人和出席会议人员资格以及表决方式、表决程序、表决结果等事 项进行见证并出具本法律意见书。 为出具本法律意见书，本所律师对达安基因本次股东会所涉事宜进行了审查， 查阅了相关会议文件，并对有关事项进行了必要的核查和验证。本所律师同意将 本法律意见书作为达安基因本次股东会公告材料，随同其他会议文件一并公告， 并依法对本法律意见书承担相应的责任。 本所律师根据相关法律、法规、规范性文件的要求，按照律师行业公认的业 ...

经历三年高增长后，国内IVD（体外诊断）龙头达安基因（002030.SZ）业绩急转直下。 根据年报，2024年，达安基因营收约8.53亿元，同比下降27.27%，净利润约-9.25亿元，同比下降 983.98%。Wind数据显示，这是达安基因近20年来首次出现净利润为负，也是其自2004年上市以来首次 亏损。 达安基因主要从事基因诊断技术及其试剂产品的研制、开发和销售，主要产品为体外诊断试剂。2020年 —2022年，借助于销售新冠病毒核酸检测试剂产品，达安基因业绩迎来高增长，三年净利润合计约 114.8亿元，约占其上市20年总盈利额的90%。 事实上，在净利润还有约1亿元的2023年，达安基因扣非净利润已从2022年的51.76亿元骤降至-3.64亿 元。对于近两年业绩下降的原因，达安基因方面均表示主要是受市场需求影响。 近日，达安基因证券部相关工作人员接受《中国经营报》记者采访表示，公司在2023年业绩下降后持续 投入科研，积极拓展新品，但受市场需求减少影响，业绩仍出现大幅亏损。该工作人员补充表示，公司 近年持续降本增效，员工人数自2023年开始减少。而关于公司对市场需求何时迎来拐点的判断，该工作 人员称 ...

Group 1: Company Overview and Strategic Goals - The company aims to become a leading integrated supplier in the in vitro diagnostic (IVD) industry, focusing on molecular diagnostics and related technologies [2][3] - The strategic goal is to align the company's industrial layout with its development objectives, emphasizing research innovation and industrial investment [2][3] Group 2: Market Expansion and Product Development - The company has fully entered the IVD field, focusing on clinical diagnostics, public health, and related applications, with plans to strengthen its PCR and molecular diagnostic markets [4][6] - The company has a comprehensive product line covering various diagnostic technologies, including molecular, immunological, biochemical, and POCT [3][6] Group 3: Financial Performance and Challenges - The company reported a significant decline in revenue and net profit in 2024, primarily due to reduced market demand and price adjustments [6][7] - The net profit attributable to shareholders was negative, influenced by increased bad debt provisions and losses from joint ventures [7][10] Group 4: Research and Development Focus - The R&D investment for 2025 will focus on promising projects, with the actual investment depending on project progress [6][10] - The company maintains a high R&D investment ratio of 45.37% of revenue, aiming to enhance product innovation and market competitiveness [10] Group 5: Competitive Strategy and Market Position - The company emphasizes self-innovation and has established multiple diagnostic technology platforms to maintain its competitive edge in the molecular diagnostics sector [5][9] - The company is actively expanding its overseas market presence, with products already shipped to over 140 countries and regions [8]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月8日至11日， 第91届中国国际医疗器械（春季）博览会（CMEF） 将在上海国家会展中心拉开帷幕。作为亚太地区规模最大的医疗科技展会，CMEF始终 是行业风向标，不仅汇聚全球创新技术，更见证着产业发展的新趋势。本届展会预计吸引 全球30多个国家和地区的近 5000家 企业，携 数万款 前沿产品集中亮相 ，以"创新科技，智领未来"为主题，共同探讨医疗科技的突破与未来。 CMEF不仅是一场产品与技术的集中展示，更是医疗行业生态的一次深度联动。从人工智能驱动的医学影像，到手术机器人赋能精准医疗，从智慧医院建设，到国 产医疗设备的崛起，CMEF2025通过高规格论坛、产业对话和技术展示，构建起全方位的交流平台，为行业发展提供新的思路与动能。 在这一医疗科技的年度盛会上，哪些企业将携最新技术亮相？哪些创新产品值得重点关注？ 思宇梳理了本届CMEF的亮点企业，一起来看它们如何在这场科技盛宴 中抢占先机！ P.S. 展位图附于文末，感兴趣的读者可按图索骥 ...

Core Viewpoint - Da An Gene has reported significant losses in its 2024 annual report, marking the largest loss in nearly 20 years, with revenue declining by 27.76% year-on-year to 853 million yuan and net losses reaching 925 million yuan, a staggering 983.98% decrease compared to the previous year [1][3] Financial Performance - The company achieved a revenue of 853 million yuan in 2024, down 27.76% year-on-year [1] - The net profit attributable to shareholders was a loss of 925 million yuan, while the net profit after deducting non-recurring items was a loss of 823 million yuan, representing declines of 983.98% and 126.11% respectively [1] - Da An Gene has made asset impairment provisions totaling 480 million yuan in 2024, with over 400 million yuan related to receivables [1] Market Dynamics - The company has faced a significant decrease in market demand and price adjustments, contributing to the decline in revenue and net profit [1] - The sales and production volume of biological products in 2024 dropped by over 80% compared to the previous year, indicating potential risks in market competitiveness [5] Historical Context - Da An Gene experienced a peak in performance during the COVID-19 pandemic, with revenues reaching 5.341 billion yuan in 2020, 7.664 billion yuan in 2021, and 12.046 billion yuan in 2022, but has since entered a period of adjustment [3] - The company has historically struggled with profitability, with significant fluctuations in net profit over the years [3] Competitive Landscape - The company has been under pressure from increased competition, leading to a decline in product prices, which has been a trend acknowledged since 2016 [4] - Despite a significant increase in the volume of molecular diagnostic products, prices have dropped significantly compared to previous years [4] Strategic Initiatives - Da An Gene has attempted to diversify its revenue streams by establishing a financial services segment since 2016, but this segment has shrunk significantly in recent years [6] - The company has indicated a focus on its core business, reducing the scale of its financial services to 30 million yuan in 2023 and 2024 [6] Management Changes - The company underwent significant changes in its shareholder and management structure, with a new controlling shareholder emerging in 2020, leading to conflicts with the previous management [7] - The current management team, led by Chairman Xue Zheqiang, faces the challenge of steering the company towards growth amidst these changes [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002030 证券简称：达安基因 公告编号：2025-007 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 ■ 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 2、报告期主要业务或产品简介 （一）公司从事的主要业务 公司是以分子诊断技术为主导的，集临床检验试剂、仪器和配套耗材的研发、生产、销售为一体的生物 医药高新技术企业。公司以成为中国一流、国际知名的体外诊断产业上下游一体化供应商为公司发展的 战略目标，公司聚焦于临床诊断技术和产品的研发，形成了以科研创新结合产业投资的产业链发展模 式，从而使公司的产业布局与公司的战略目标紧密地保持一致。经过近三十年的不断地发展，公司业务 范围涵盖了以分子诊断技术、免疫诊断技术、生 ...